Letter to the Editor
JBCGenetics. 2022; 5(2):

Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia

Authors: Amsal Qureshi, Areesha Moiz Alvi.

View PDF HTML Fulltext DOI: 10.24911/JBCGenetics/183-1653668216

Abstract

No abstract available

Keywords:   Achondroplasia, Vosoritide, FGFR3, children, CNP


© Copyright: Author(s)

Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia


Authors
Amsal Qureshi
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
PubMed articlesGoogle scholar articles

Areesha Moiz Alvi
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
PubMed articlesGoogle scholar articles


Correspondence to:
. Areesha Moiz Alvi, Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.; areeshamoizalvi@gmail.com

Publication history
Received 27 May 2022
Revised 09 Jul 2022
Accepted 16 Oct 2022
Published online 05 Nov 2022

How to cite this article

Pubmed Style

Qureshi A, Alvi AM. Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. JBCGenetics. Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Web Style

Qureshi A, Alvi AM. Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. https://www.jbcgenetics.com//?mno=49693 [Access: November 28, 2022]. doi:10.24911/JBCGenetics/183-1653668216


AMA (American Medical Association) Style

Qureshi A, Alvi AM. Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. JBCGenetics. Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Vancouver/ICMJE Style

Qureshi A, Alvi AM. Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. JBCGenetics, [cited November 28, 2022]; Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Harvard Style

Qureshi, A. & Alvi, . A. M. (2022) Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. JBCGenetics, Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Turabian Style

Qureshi, Amsal, and Areesha Moiz Alvi. 2022. Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. Journal of Biochemical and Clinical Genetics, Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Chicago Style

Qureshi, Amsal, and Areesha Moiz Alvi. "Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia." Journal of Biochemical and Clinical Genetics Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


MLA (The Modern Language Association) Style

Qureshi, Amsal, and Areesha Moiz Alvi. "Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia." Journal of Biochemical and Clinical Genetics Online First: 05 Nov, 2022. Web. 28 Nov 2022 doi:10.24911/JBCGenetics/183-1653668216


APA (American Psychological Association) Style

Qureshi, A. & Alvi, . A. M. (2022) Vosoritide: a drug providing a promising avenue for the treatment of short stature in children with Achondroplasia. Journal of Biochemical and Clinical Genetics, Online First: 05 Nov, 2022. doi:10.24911/JBCGenetics/183-1653668216


Click the icon of the social media platform on which you would like to share this article.